GeneMedicine(GM) is a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies, aiming to transform the therapeutic outcomes for cancer patients. Using our proprietary adenovirus platform, we're developing several pipeline products that can be intratumorally and intravenously administered to selectively attack and eradicate tumor cells as well as potently stimulating multiple arms of antitumor immune response. Our viral immunotherapy has proven effective as both a standalone therapy and in combination with current standard of care, including immune checkpoint inhibitors (ICI).

Intratumoral administration of GM oncolytic adenovirus offers several advantages over competitor products; (1) higher level of virus accumulation and localization in tumor tissues and (2) lower off-target systemic exposure, ultimately exerting potent therapeutic effect with minimal systemic toxicity. Our pipeline can effectively treat wide range of tumor types, including breast cancers (triple-negative and hormone receptor-positive), prostate cancer, melanoma, and non-melanoma skin cancer, desmoplastic cancers (like pancreatic cancer), and injectable visceral tumors that have spread to the liver, such as metastases from colorectal and lung cancer. To treat metastatic and recurrent cancers in late-stage cancer patients, we've developed systemic delivery platform for oncolytic viruses that avoids rapid blood clearance and inactivation by the immune system and various blood components.

GM’s potent multi-armed oncolytic viral platform GM-OAd mediated oncolysis results in immunogenic cell death to trigger robust antitumor immune activation and memory formation to ensure long-term therapeutic benefit against cancer. GM has a highly scalable, low cost manufacturable platform offering highly versatile, innovative treatment options for patients with advanced or metastatic tumors.

Biotechnology

GeneMedicine

Chae-Ok Yun

Teams at GeneMedicine

Leadership Team